Completed PHASE4 INTERVENTIONAL 2-arm NCT01119638

Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone (EscBPSD)

Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients

Sponsor: Abarbanel Mental Health Center

Conditions Agitation Alzheimer's Disease Psychosis

Interventions Escitalopram Risperidone

Updated 7 times since 2017 Last updated: Jun 23, 2015 Started: Apr 30, 2008 Primary completion: Apr 30, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01119638, this PHASE4 trial focuses on Agitation and Alzheimer's Disease and remains completed. Sponsored by Abarbanel Mental Health Center, it has been updated 7 times since 2008, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abarbanel Mental Health Center

Data source: Abarbanel Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bat Yam, Israel